Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Histopathology
    August 2025
  1. NEIL AJ, Nkosi D, Yoon JY, Kolin DL, et al
    Molecular and immunohistochemical characterization of ERBB2 activating mutations in low-grade serous ovarian carcinoma.
    Histopathology. 2025;87:310-320.
    >> Share

    November 2024
  2. ZHANG X, McCluggage WG, Howitt BE, Hirsch MS, et al
    SOX17 expression in mesonephric-like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Mullerian biomarker.
    Histopathology. 2024;85:820-825.
    >> Share

  3. DEHGHANI A, Sharma AE, Siegmund SE, Carreon CK, et al
    STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours.
    Histopathology. 2024;85:769-782.
    >> Share

  4. X ZHANG G, Yang B
    Retained PAX2 expression associated with DNA mismatch repair deficiency in endometrial endometrioid adenocarcinoma.
    Histopathology. 2024;85:794-803.
    >> Share

    October 2024
  5. RICCI C, Ambrosi F, Grillini A, Grillini M, et al
    Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma.
    Histopathology. 2024;85:695-698.
    >> Share

  6. ALAFRAIDI M, Hoang L, Howitt BE, Longacre TA, et al
    The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile.
    Histopathology. 2024;85:660-670.
    >> Share

  7. MCHENRY A, Devereaux K, Ryan E, Chow S, et al
    Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low- and high-stage tumours.
    Histopathology. 2024;85:614-626.
    >> Share

  8. WYVEKENS N, Mutter GL, Nucci MR, Kolin DL, et al
    Lesions sub-diagnostic of endometrioid intra-epithelial neoplasia/atypical hyperplasia: value of morphology and immunohistochemistry in predicting neoplastic outcome.
    Histopathology. 2024;85:579-589.
    >> Share

    June 2024
  9. PARRA-HERRAN C, Dundr P, McCluggage WG
    Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Histopathology. 2024;84:1092-1094.
    >> Share

  10. KOBEL M, Kang EY, Lee S, Terzic T, et al
    Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Histopathology. 2024;84:1095-1110.
    >> Share

    May 2024
  11. ANGELICO G, Salvatorelli L, Tinnirello G, Santoro A, et al
    The first evidence of mismatch repair deficiency in mesonephric-like adenocarcinoma of the endometrium: clinicopathological and molecular features of a case emphasising a possible endometrioid carcinogenesis.
    Histopathology. 2024;84:1068-1070.
    >> Share

    March 2024
  12. KOMMOSS FKF
    Lessons from genomic profiling: towards a molecular-based classification of ovarian Sertoli-Leydig cell tumour.
    Histopathology. 2024;84:712-714.
    >> Share

  13. KOMMOSS FKF, Chong AS, Apellaniz-Ruiz M, Turashvili G, et al
    Teratoma-associated and so-called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features.
    Histopathology. 2024;84:683-696.
    >> Share

    January 2024
  14. MCCLUGGAGE WG
    Editorial on: Role of gene sequencing in classifying struma ovarii: BRAF P.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Histopathology. 2024;84:288-290.
    >> Share

  15. NEIL AJ, Li YY, Hakam A, Nucci MR, et al
    Pattern A endocervical adenocarcinomas with ovarian metastasis are indolent and molecularly distinct from destructively invasive adenocarcinomas.
    Histopathology. 2024;84:369-380.
    >> Share

  16. NEYRAND S, Trecourt A, Lopez J, Just PA, et al
    Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Histopathology. 2024;84:291-300.
    >> Share

    September 2023
  17. MACHUCA-AGUADO J, McCluggage WG
    'STIC-like' lesions in ovarian low-grade serous carcinoma: a diagnostic pitfall.
    Histopathology. 2023;83:489-492.
    >> Share

  18. RICCI C, Ambrosi F, Franceschini T, Giunchi F, et al
    FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type.
    Histopathology. 2023;83:465-476.
    >> Share

    July 2023
  19. THORNE H, Devereux L, Li J, Alsop K, et al
    BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
    Histopathology. 2023;83:91-103.
    >> Share

  20. BOGAERTS JMA, van Bommel MHD, Hermens RPMG, Steenbeek MP, et al
    Consensus based recommendations for the diagnosis of serous tubal intraepithelial carcinoma: an international Delphi study.
    Histopathology. 2023;83:67-79.
    >> Share

    June 2023
  21. MIRKOVIC J, Olkhov-Mitsel E, Amemiya Y, Al-Hussaini M, et al
    Mesonephric-like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas.
    Histopathology. 2023;82:978-990.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016